



## Antibody Therapeutics against Infectious Disease

Guest Editors:

**Prof. Dr. Susan Sharfstein**

College of Nanoscale Science  
and Engineering, The State  
University of New York  
Polytechnic Institute, Albany, NY  
12203, USA

**Dr. Hanieh Khalili**

School of biomedical science,  
University of West London,  
London W5 5RF, UK

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### Message from the Guest Editors

Bioengineering is currently soliciting manuscripts for a special issue focusing on novel antibody therapeutics used to treat infectious disease. Manuscripts can include literature reviews as well as primary research papers. Topics of particular interest include platforms for rapid discovery of antibodies, bispecific antibodies, strategies for rapid manufacturing to respond to emerging diseases, and repurposing of existing antibody therapeutics for novel indications in infectious disease. Submissions related to treatment of SARS-CoV2/COVID19 are particularly encouraged, but papers addressing other infectious diseases such as respiratory syncytial virus (RSV), Zika and Ebola viruses are also welcome.

Submissions are requested by May 2021 and will be peer-reviewed and published once submitted, possible publication date September 2021. Bioengineering (ISSN 2306-5354; CODEN: BIOENG) is an international scientific peer-reviewed, open access journal on the science and technology of bioengineering, published monthly online by MDPI.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Anthony Guiseppi-Elie**

Department of Biomedical  
Engineering, Texas A&M  
University, College Station, TX  
77843, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPlus / SciFinder](#), [Inspec](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Engineering, Biomedical*)

## Contact Us

---

*Bioengineering* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/bioengineering](http://mdpi.com/journal/bioengineering)  
[bioengineering@mdpi.com](mailto:bioengineering@mdpi.com)  
[X@Bioeng\\_MDPI](https://twitter.com/Bioeng_MDPI)